Ecolab
Delivers industrial water-treatment, hygiene, purification, and pest-control programs through a direct service network.
Something off on this page? Send us feedback.
Profile
Provides water-treatment and process chemistry, institutional cleaning and sanitation, biopharma contamination-control and purification products, and commercial pest services. Revenue comes from consumables, equipment, digital tools, and recurring field service delivered through a large direct sales-and-service network at industrial and institutional sites worldwide.
Provides water treatment and process chemistry through Global Water; cleaning and sanitation through Global Institutional & Specialty; commercial pest management through Global Pest Elimination; and biopharma contamination control, decontamination, and purification through Global Life Sciences. Ovivo Electronics' ultrapure-water systems and CoolIT's direct liquid-cooling equipment extend the water portfolio into semiconductor fabrication and data centers.
Combines consumable chemistry with monitoring, dispensing and treatment equipment, digital tools, and a direct field-service network to manage water use, hygiene, product quality, and operating efficiency at customer sites. Operations span the world, with the United States the largest market and nearly half of sales generated elsewhere.
Depends on technical coverage at customer facilities, access to chemicals and equipment components, and product registrations governing pesticides, biocides, medical devices, drugs, and food-contact antimicrobials.
Company facts
Key statistics
Year to date +9.2% · Average volume (30d) 1.4M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Jul 29, 2026 | UBS | Reiterate | Buy | $325 | $342 | |
| Jul 29, 2026 | BMO Capital | Reiterate | Outperform | $345 | $360 | |
| Jul 29, 2026 | Mizuho Securities | Target | $335 | $327 | ||
| Jul 29, 2026 | Robert W. Baird | Target | $327 | $305 | ||
| Jul 17, 2026 | Oppenheimer | Reiterate | Outperform | $320 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Jul 28, 2026Q2 FY26 | $2.08 | $2.09 | +0.5% | $4.38B | $4.42B | +0.7% | +0.28% |
| Apr 28, 2026Q1 FY26 | $1.70 | $1.70 | 0.0% | $4.03B | $4.07B | +1.0% | −3.88% |
| Feb 10, 2026Q4 FY25 | $2.07 | $2.08 | +0.5% | $4.19B | $4.19B | +0.1% | +1.31% |
| Oct 28, 2025Q3 FY25 | $2.07 | $2.07 | 0.0% | $4.12B | $4.17B | +1.1% | −4.03% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $3.70B | $4.03B | $4.17B | $4.20B | $4.07B | $4.42B | |
| Gross profit | $1.64B | $1.80B | $1.87B | $1.85B | $1.77B | $1.95B | |
| Operating income | $586.8M | $710.1M | $760.2M | $785.9M | $622.0M | $757.9M | |
| Net income | $402.5M | $524.2M | $585.0M | $563.9M | $432.6M | $534.9M | |
| Diluted EPS | $1.41 | $1.84 | $2.05 | $1.98 | $1.52 | $1.90 | |
| Gross margin | 44.3% | 44.8% | 44.8% | 44.0% | 43.6% | 44.1% | |
| Operating margin | 15.9% | 17.6% | 18.3% | 18.7% | 15.3% | 17.2% |
Fiscal years (4-quarter sums)FY21 $12.73B · FY22 $14.19B · FY23 $15.32B · FY24 $15.74B · FY25 $16.08B
Revenue by product · Q2 FY26
Revenue by geography · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $5.14B · Total debt $13.75B · Total assets $29.93B · Shareholders' equity $10.06B
Dividends
Raised for 38 straight years — most recently to $0.73 from $0.65 in Dec 2025. To collect a payout, hold shares through the close before the ex-date.
History
| Ex-date | Record | Paid | Amount | Note |
|---|---|---|---|---|
| Jun 16, 2026 | Jun 16 | Jul 15 | $0.73 | |
| Mar 17, 2026 | Mar 17 | Apr 15 | $0.73 | |
| Dec 16, 2025 | Dec 16 | Jan 15 | $0.73 | raised from $0.65 |
| Sep 16, 2025 | Sep 16 | Oct 15 | $0.65 | |
| Jun 17, 2025 | Jun 17 | Jul 15 | $0.65 | |
| Mar 18, 2025 | Mar 18 | Apr 15 | $0.65 | |
| Dec 17, 2024 | Dec 17 | Jan 15 | $0.65 | raised from $0.57 |
| Sep 17, 2024 | Sep 17 | Oct 15 | $0.57 |
Ownership
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 281.44M · Float 251.79M · 89.5% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 23.05M | 8.19% | 13F | Aug 7, 2026 |
| Vanguard Capital Management LLC | 16.54M | 5.88% | 13F | Aug 13, 2026 |
| JPMorgan Chase & Co | 14.45M | 5.10% | 13G | Jul 16, 2026 |
| State Street Corp | 11.77M | 4.18% | 13F | Aug 7, 2026 |
| Morgan Stanley | 7.83M | 2.78% | 13F | Aug 13, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 18, 2026 | Christophe Beck | director, officer: CHAIRMAN, PRESIDENT & CEO | −17,862 | $280.14 |
| Aug 11, 2026 | Gregory B. Cook | officer: Co-COO - Global Businesses | −4,567 | $285.13 |
| Jul 30, 2026 | Scott D. Kirkland | officer: CHIEF FINANCIAL OFFICER | −3,357 | $276.96 |
| Jun 11, 2026 | Benjamin M. Clark | officer: EVP - Global Supply Chain | +1,000 | $263.83 |
| Jun 10, 2026 | Michel D. Doukeris | director | +7,750 | $258.00 |
Peers
- Veralto
Danaher spin-off; ChemTreat and Hach contest Nalco Water in industrial treatment
- Rentokil Initial (ADR)
World's #1 pest control company; competes in commercial pest and hygiene
- Rollins
World's #2 pest control company; 10-K names Ecolab as a major competitor
- STERIS
Primary rival in biopharma contamination control and healthcare sterility
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Ecolab | $275.05 | −4.11% | $80.70B | 38.5 | 33.2 | 4.8 | +9.7% |
| Veralto | $97.11 | −1.38% | $24.03B | 24.9 | 21.8 | 4.2 | +7.5% |
| Rentokil Initial (ADR) | $23.53 | +0.02% | $11.84B | 50.1 | — | 1.4 | −21.7% |
| Rollins | $36.24 | −0.38% | $17.50B | 33.1 | 30.4 | 4.5 | +7.9% |
| STERIS | $233.78 | +0.06% | $22.78B | 28.6 | 20.4 | 3.8 | +7.8% |
| Median | 30.8 | 21.8 | 4.0 | +7.7% |